Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
BLCO

Bausch + Lomb Corporation

BLCO

15.66USD+0.32 (+2.09%)Market Closed
Watchlist

Market Summary

USD15.66+0.32
Market Closed
2.09%

BLCO Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

BLCO Stock Price

View Fullscreen

BLCO RSI Chart

BLCO Valuation

Market Cap

5.5B

Price/Earnings (Trailing)

-26.54

Price/Sales (Trailing)

1.38

EV/EBITDA

10.72

Price/Free Cashflow

-274.7

BLCO Price/Sales (Trailing)

BLCO Profitability

Free Cashflow Yield

-0.36%

BLCO Fundamentals

BLCO Revenue

Revenue (TTM)

4.0B

Revenue Y/Y

6.9%

Revenue Q/Q

-2.71%

BLCO Earnings

Earnings (TTM)

-207.0M

Earnings Y/Y

-366.67%

Earnings Q/Q

-162.5%

Price Action

Last 7 days

1.4%

Last 30 days

-5.1%

Last 90 days

-9.2%

Trailing 12 Months

3.3%

How does BLCO drawdown profile look like?

BLCO Financial Health

BLCO Investor Care

Shares Dilution (1Y)

0.24%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.8B3.9B4.0B0
20223.8B3.8B3.8B3.8B
20213.5B3.6B3.7B3.8B
20200003.4B

Latest Insider Trading transactions for BLCO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 29, 2023
de schutter richard u
acquired
26,865
16.95
1,585
-
Sep 29, 2023
paulson john
acquired
21,865
16.95
1,290
-
Sep 29, 2023
robertson russel c
acquired
25,611
16.95
1,511
-
Sep 29, 2023
bernier nathalie d.
acquired
24,984
16.95
1,474
-
Jul 25, 2023
munsch frederick
sold (taxes)
-26,023
19.82
-1,313
svp, controller and cao
Jul 25, 2023
eldessouky sam
sold (taxes)
-83,600
19.82
-4,218
evp and cfo
Jul 25, 2023
hashad yehia
sold (taxes)
-79,200
19.82
-3,996
evp of r&d and cmo
Jul 25, 2023
bonnefoy luc
sold (taxes)
-44,396
19.82
-2,240
president, surgical
Jun 30, 2023
bernier nathalie d.
acquired
24,987
20.07
1,245
-
Jun 30, 2023
robertson russel c
acquired
25,609
20.07
1,276
-

1–10 of 50

Which funds bought or sold BLCO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-95.56
-588,904
23,165
-%
Nov 29, 2023
Alamar Capital Management, LLC
sold off
-100
-2,192,350
-
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-46.5
-1,144,980
943,741
-%
Nov 15, 2023
JANE STREET GROUP, LLC
added
64.08
130,539
468,939
-%
Nov 14, 2023
Quadrature Capital Ltd
new
-
465,637
465,637
0.01%
Nov 14, 2023
Alberta Investment Management Corp
added
39.1
3,409,000
22,912,900
0.24%
Nov 14, 2023
ArrowMark Colorado Holdings LLC
sold off
-100
-4,714,460
-
-%
Nov 14, 2023
CASPIAN CAPITAL LP
unchanged
-
-1,039,350
5,646,450
13.98%
Nov 14, 2023
Covalent Partners LLC
unchanged
-
-38,064
206,790
0.66%
Nov 14, 2023
MANGROVE PARTNERS
sold off
-100
-19,415,700
-
-%

1–10 of 42

Latest Funds Activity

Are funds buying BLCO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BLCO
No. of Funds

Schedule 13G FIlings of Bausch + Lomb Corporation

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
bausch health companies inc.
88.7%
310,449,643
SC 13G

Recent SEC filings of Bausch + Lomb Corporation

View All Filings
Date Filed Form Type Document
Nov 13, 2023
8-K/A
Current Report
Nov 07, 2023
8-K/A
Current Report
Nov 01, 2023
8-K
Current Report
Nov 01, 2023
10-Q
Quarterly Report
Oct 03, 2023
4
Insider Trading
Oct 03, 2023
4
Insider Trading
Oct 03, 2023
4
Insider Trading
Oct 03, 2023
4
Insider Trading
Sep 29, 2023
8-K
Current Report
Sep 14, 2023
8-K
Current Report

Bausch + Lomb Corporation News

Latest updates
Yahoo Finance02 Nov 202307:00 am36 days ago
Yahoo Canada Finance26 Oct 202307:00 am43 days ago
The Globe and Mail13 Oct 202307:00 am56 days ago
Zonebourse.com12 Sep 202307:00 am2 months ago
Yahoo Finance05 Aug 202307:00 am4 months ago
The Motley Fool04 Aug 202207:00 am16 months ago
The Globe and Mail20 Jul 202207:00 am16 months ago
Canada NewsWire10 May 202207:00 am19 months ago
PR Newswire06 May 202207:00 am19 months ago

Financials for Bausch + Lomb Corporation

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue-2.7%1,0071,0359319969429418891,001949934881-
Costs and Expenses-2.5%967992933945896885835909855876796-
  S&GA Expenses0.2%418417418386381368343365348358318-
Interest Expenses31.0%76.0058.0050.0047.0035.0044.0020.00-----
Income Taxes350.0%45.0010.0033.00-2.0034.0020.006.0032.0025.0021.0047.00-
Earnings Before Taxes-84.2%-35.00-19.00-55.00-2.0019.0027.0029.0086.0088.0067.0077.00-
Net Income-162.5%-84.00-32.00-90.00-1.00-18.005.0020.0051.0060.0044.0027.00-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets15.5%13,06811,31511,16911,14410,69611,00210,90710,823
  Current Assets6.4%2,4642,3152,1842,1371,8592,0011,7191,635
    Cash Equivalents-6.2%360384346354287446190177
  Inventory7.9%754699697628605606598572
  Net PPE-0.8%1,2841,2941,2961,3001,2221,2431,2251,225
  Goodwill-0.3%4,5264,5404,5224,5074,4154,4934,5534,586
Liabilities44.3%6,1854,2854,1174,0433,9014,0313,6911,421
  Current Liabilities4.6%1,3861,3251,2541,2961,1991,2731,0921,099
    LT Debt, Current20.0%30.0025.0025.0025.0025.0025.00--
    LT Debt, Non Current70.3%4,4352,6042,5082,4112,4132,417--
Shareholder's Equity-1.1%6,8836,9587,0527,0336,7296,9717,2169,402
  Retained Earnings-72.4%-200-116-84.006.007.0025.0020.00-
  Additional Paid-In Capital0.2%8,3348,3218,3058,2858,1088,0888,219-
Shares Outstanding0.1%351351350350350350350350
Minority Interest-8.3%66.0072.0069.0068.0066.0075.0076.0073.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations300.0%48,000-24,000-56,000159,00027,000156,0003,000162,000273,000250,000188,000-
  Share Based Compensation-11.1%16,00018,00024,00017,00018,00011,00016,00017,00016,00015,00014,000-
Cashflow From Investing-6621.4%-1,882,000-28,000-64,000-90,000-49,000-35,000-41,000-81,000-40,000-45,000-48,000-
Cashflow From Financing1912.2%1,811,00090,00091,000-7,000-109,000145,00052,000-37,000-378,000-183,000-114,000-

BLCO Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Total revenues$ 1,007$ 942$ 2,973$ 2,772
Expenses    
Selling, general and administrative (Note 4)4183811,2531,092
Research and development (Note 4)8277244229
Amortization of intangible assets4759160188
Other expense, net287548
Total expenses9678962,8922,616
Operating income404681156
Interest income42123
Interest expense (Note 4)(76)(35)(184)(99)
Foreign exchange and other(3)6(18)15
(Loss) income before provision for income taxes(35)19(109)75
Provision for income taxes(45)(34)(88)(60)
Net (loss) income(80)(15)(197)15
Net income attributable to noncontrolling interest(4)(3)(9)(8)
Net (loss) income attributable to Bausch + Lomb Corporation$ (84)$ (18)$ (206)$ 7
Basic (loss) income per share attributable to Bausch + Lomb Corporation (in usd per share)$ (0.24)$ (0.05)$ (0.59)$ 0.02
Diluted (loss) income per share attributable to Bausch + Lomb Corporation (in usd per share)$ (0.24)$ (0.05)$ (0.59)$ 0.02
Basic weighted-average common shares (in shares)350.8350.0350.4350.0
Diluted weighted-average common shares (in shares)350.8350.0350.4350.1
Product sales    
Revenues    
Total revenues$ 1,004$ 937$ 2,963$ 2,755
Expenses    
Cost of goods sold (excluding amortization and impairments of intangible assets) (Note 4) and Cost of other revenues3913701,1791,093
Other revenues    
Revenues    
Total revenues351017
Expenses    
Cost of goods sold (excluding amortization and impairments of intangible assets) (Note 4) and Cost of other revenues$ 1$ 2$ 2$ 6

BLCO Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 355$ 354
Restricted cash526
Trade receivables, net (Note 4)783724
Inventories, net754628
Prepaid expenses and other current assets (Note 4)567405
Total current assets2,4642,137
Property, plant and equipment, net1,2841,300
Intangible assets, net3,6622,058
Goodwill4,5264,507
Deferred tax assets, net920927
Other non-current assets (Note 4)212215
Total assets13,06811,144
Current liabilities:  
Accounts payable (Note 4)364370
Accrued and other current liabilities992901
Current portion of long-term debt3025
Total current liabilities1,3861,296
Deferred tax liabilities, net117
Other non-current liabilities353329
Long-term debt4,4352,411
Total liabilities6,1854,043
Commitments and contingencies (Note 17)
Equity  
Common shares, no par value, unlimited shares authorized, 350,824,535 and 350,000,749 issued and outstanding at September 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital8,3348,285
Accumulated (deficit) earnings(200)6
Accumulated other comprehensive loss(1,317)(1,258)
Total Bausch + Lomb Corporation shareholders’ equity6,8177,033
Noncontrolling interest6668
Total equity6,8837,101
Total liabilities and equity$ 13,068$ 11,144
BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
 CEO
 WEBSITEwww.bausch.com
 EMPLOYEES13000

Bausch + Lomb Corporation Frequently Asked Questions


What is the ticker symbol for Bausch + Lomb Corporation? What does BLCO stand for in stocks?

BLCO is the stock ticker symbol of Bausch + Lomb Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch + Lomb Corporation (BLCO)?

As of Fri Dec 08 2023, market cap of Bausch + Lomb Corporation is 5.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart. The fair value of Bausch + Lomb Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bausch + Lomb Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLCO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bausch + Lomb Corporation a good stock to buy?

The fair value guage provides a quick view whether BLCO is over valued or under valued. Whether Bausch + Lomb Corporation is cheap or expensive depends on the assumptions which impact Bausch + Lomb Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCO.

What is Bausch + Lomb Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, BLCO's PE ratio (Price to Earnings) is -26.54 and Price to Sales (PS) ratio is 1.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCO PE ratio will change depending on the future growth rate expectations of investors.